Sökning: WFRF:(Widner Håkan) >
Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (R) (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess (R)/Comtan (R) (Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment
-
Brooks, D J (författare)
-
Agid, Y (författare)
-
Eggert, K (författare)
-
visa fler...
-
- Widner, Håkan (författare)
- Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Ostergaard, K (författare)
-
Holopainen, A (författare)
-
visa färre...
-
(creator_code:org_t)
- 2005-07-29
- Engelska.
-
Ingår i: European Neurology. - : S. Karger AG. - 1421-9913 .- 0014-3022. ; 53:4, s. 197-202
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The aim of this study was to evaluate the efficacy of the new optimised levoclopa, Stalevo(R) (levoclopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-close wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCl) formulations along with adjunct entacapone (Comtess(R)/Comtan(R)). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCl to either an equivalent dose of Stalevo or levodopa/DDCl plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson's Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo, and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCl plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCl and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCl preparations.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- wearing-off
- catechol-O-methyltransferase inhibition
- inhibitor
- dopa-decarboxylase
- levodopa
- Parkinson's disease
- Stalevo (R)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)